

January 2024

Dear Valued Partner,*

Thank you for your interest, participation and commitment to clinical research that is advancing the collective understanding of rare diseases.

At Amicus Therapeutics, we view every person who participates in a clinical study as our partner in the drug development process. We know that clinical research could not be done without you. We also recognize that participating in a clinical study requires dedication and sacrifice, and that fulfilling the study's many requirements can be challenging. That is why the Amicus Patient & Professional Advocacy (P&PA) team is dedicated to supporting study participants and connecting them with resources they need, before, during and after the study. To learn more about Patient & Professional Advocacy please visit Amicus Therapeutics website: www.amicusrx.com or our dedicated website for patients at: www.communityofus.com.

The educational resources included in the pull-down menu on the Community of Us website connect you to a variety of Amicus informative brochures and clinical trial updates. The brochures provide easy-to-read information about the essential role of clinical studies in the development of new treatments. We hope you'll find them interesting and empowering.

On behalf of everyone at Amicus, thank you again for your interest in learning more or participating in one of our current clinical studies. We also extend our gratitude to your family, friends and the broader rare disease community who are helping make your participation possible. Together we can make a difference.

With warm regards,



Bradley L. Campbell
President and CEO



Jayne C. Gershkowitz
Chief Patient Advocate

*Please note: Amicus respects and abides by all personal data privacy regulations. As the study sponsor, Amicus does not know the identities of individuals participating in its clinical research.

Amicus Therapeutics, Inc.

Phone: 215.921.7600 | Fax: 215.921.7900 | www.amicusrx.com